SK-JHRCC-120 is a human clear cell renal cell carcinoma (ccRCC) cell line that displays epithelial morphology and grows in adherent culture. This cell line forms big colonies when plated in soft agar. The SK-JHRCC-120 cells are a useful preclinical model to study renal cancer. They form tumors when inoculated subcutaneously in immunocompromised NSG mice. These xenografts are insensitive to Sunitinib (oral, small molecule, multi-targeted receptor tyrosine kinase inhibitor, approved for the treatment of renal cell carcinoma) in vivo.
This cell line was established in 2013 from the primary tumor of a 49-year-old Caucasian male with clear cell carcinoma of the kidney and was refractory to treatment with Sunitinib.
- James J. Hsieh, MD, PhD, Laboratory Head, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
- Emily H. Cheng, MD, PhD, Laboratory Head, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
- Yiyu Dong, PhD, Research Associate, Hsieh Laboratory, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
This cell line may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, email@example.com
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, firstname.lastname@example.org